Should I buy or sell GT Biopharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GT Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" GTBP shares. View GTBP analyst ratings or view top-rated stocks .

What is GT Biopharma's stock price target for 2024?

1 brokerages have issued 1 year price targets for GT Biopharma's stock. Their GTBP share price targets range from $150.00 to $150.00. On average, they expect the company's share price to reach $150.00 in the next twelve months. This suggests a possible upside of 1,823.1% from the stock's current price. View analysts price targets for GTBP or view top-rated stocks among Wall Street analysts .

How have GTBP shares performed in 2024?

GT Biopharma's stock was trading at $7.65 at the beginning of the year. Since then, GTBP stock has increased by 2.0% and is now trading at $7.80. View the best growth stocks for 2024 here .

When is GT Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our GTBP earnings forecast .

How were GT Biopharma's earnings last quarter?

GT Biopharma, Inc. (NASDAQ:GTBP) announced its quarterly earnings results on Thursday, April, 15th. The company reported ($101.70) EPS for the quarter, missing analysts' consensus estimates of ($1.20) by $100.50.

When did GT Biopharma's stock split?

GT Biopharma's stock reverse split before market open on Monday, February 5th 2024. The 1-30 reverse split was announced on Monday, February 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of GT Biopharma?

Shares of GTBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GTBP

GT Biopharma (GTBP) Stock Price, News & Analysis

→ Everybody laughed when he recommended Netflix (From Stansberry Research) (Ad)

Free GTBP Stock Alerts

Notice: Trading of GT Biopharma halted at 09:42 AM EST due to "LULD pause".

$7.80

+4.68 (+150.00%)

(As of 04:27 PM ET)

Compare

Today's Range: $6.66
▼
$10.66
50-Day Range: $3.00
▼
$5.07
52-Week Range: $2.95
▼
$16.11

Volume: 64.56 million shs
Average Volume: 683,435 shs
Market Capitalization: $11.08 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $150.00

GT Biopharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,823.1% Upside
$150.00 Price Target
Short Interest: Healthy
0.48% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.72
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.47 out of 5 stars

Medical Sector

631st out of 917 stocks

Pharmaceutical Preparations Industry

295th out of 428 stocks

3.5

Analyst's Opinion

Consensus Rating
GT Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
GT Biopharma has received no research coverage in the past 90 days.
Read more about GT Biopharma's stock forecast and price target.

3.0

Short Interest

Percentage of Shares Shorted
0.48% of the float of GT Biopharma has been sold short.
Short Interest Ratio / Days to Cover
GT Biopharma has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in GT Biopharma has recently increased by 81.82%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
GT Biopharma does not currently pay a dividend.
Dividend Growth
GT Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GTBP.

2.6

News and Social Media Coverage

News Sentiment
GT Biopharma has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for GT Biopharma this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for GTBP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added GT Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GT Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 10.00% of the stock of GT Biopharma is held by insiders.
Percentage Held by Institutions
Only 8.15% of the stock of GT Biopharma is held by institutions.
Read more about GT Biopharma's insider trading history.

0.0

Earnings and Valuation

Price to Book Value per Share Ratio
GT Biopharma has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
Read more about GT Biopharma's valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

Everybody laughed when he recommended Netflix

"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined.

Click here to see how it could become the No. 1 investment of the next decade.

About GT Biopharma Stock (NASDAQ:GTBP)

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

GTBP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GTBP Stock News Headlines

May 20 at 8:40 AM | investorplace.com

Why Is GT Biopharma (GTBP) Stock Up 143% Today?

May 18 at 10:04 AM | nasdaq.com

GT Biopharma, Inc. Common Stock (GTBP)

May 18 at 2:11 AM | americanbankingnews.com

GT Biopharma (NASDAQ:GTBP) Stock Price Down 4.6%

May 16, 2024 | benzinga.com

Raymond W. Urbanski's Net Worth

May 16, 2024 | investorplace.com

GTBP Stock Earnings: GT Biopharma Beats EPS for Q1 2024

May 15, 2024 | msn.com

GT Biopharma reports Q1 results

May 15, 2024 | globenewswire.com

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

March 27, 2024 | benzinga.com

Recap: GT Biopharma Q4 Earnings

March 26, 2024 | globenewswire.com

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

February 25, 2024 | msn.com

GT Biopharma (GTBP) Price Target Increased by 2900.00% to 153.00

February 14, 2024 | finance.yahoo.com

GTBP Feb 2024 2.500 call

February 2, 2024 | finance.yahoo.com

GT Biopharma, Inc. (GTBP)

February 2, 2024 | msn.com

GT Biopharma Announces Reverse Stock Split Update

February 2, 2024 | benzinga.com

GT Biopharma Stock (NASDAQ:GTBP), Short Interest Report

February 1, 2024 | finance.yahoo.com

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

December 14, 2023 | markets.businessinsider.com

Buy Rating for GT Biopharma: High Efficacy and Expanded Potential in Oncology Therapeutics

December 6, 2023 | finance.yahoo.com

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

December 4, 2023 | msn.com

GT Biopharma submits IND to FDA for CD33+ leukemia therapy

December 4, 2023 | finance.yahoo.com

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

November 23, 2023 | markets.businessinsider.com

GT Biopharma: Strong Q3 Performance and Promising Pipeline Progression Justify Buy Rating

November 6, 2023 | finance.yahoo.com

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

November 1, 2023 | msn.com

GT Biopharma GAAP EPS of -$0.06

November 1, 2023 | finance.yahoo.com

GT Biopharma Reports Third Quarter 2023 Financial Results

August 24, 2023 | finance.yahoo.com

GT Biopharma, Inc. (GTBP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

August 8, 2023 | markets.businessinsider.com

H.C. Wainwright Remains a Buy on GT Biopharma (GTBP)

See More Headlines

Company Calendar

Last Earnings: 4/15/2021
Today: 5/20/2024
Next Earnings (Estimated): 8/05/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GTBP
Previous Symbol: OTCMKTS:OXISD
CUSIP: N/A
CIK: 109657
Web: www.gtbiopharma.com
Phone: (415) 919-4040
Fax: N/A
Employees: 2
Year Founded: 1965

Price Target and Rating

Average Stock Price Target: $150.00
High Stock Price Target: $150.00
Low Stock Price Target: $150.00
Potential Upside/Downside: +4,707.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,600,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -135.49%
Return on Assets: -80.28%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.15
Quick Ratio: 2.12

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.75 per share
Price / Book: 0.83

Miscellaneous

Outstanding Shares: 1,417,000
Free Float: 1,275,000
Market Cap: $4.42 million
Optionable: Optionable
Beta: 0.65

Social Links

Key Executives

Mr. Michael Martin Breen (Age 61)
Interim CEO & Executive Chairman
Comp: $1.09M
Mr. Manu Ohri (Age 69)
CFO & Secretary
Comp: $544.87k
Dr. Jeffrey S. Miller M.D.
Consulting Chief Scientific Officer, Consulting Chief Medical Officer & Scientific Advisor

Key Competitors

View All Competitors

GTBP Stock Analysis - Frequently Asked Questions

Should I buy or sell GT Biopharma stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GT Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" GTBP shares.
View GTBP analyst ratings or view top-rated stocks.
What is GT Biopharma's stock price target for 2024?: 1 brokerages have issued 1 year price targets for GT Biopharma's stock. Their GTBP share price targets range from $150.00 to $150.00. On average, they expect the company's share price to reach $150.00 in the next twelve months. This suggests a possible upside of 1,823.1% from the stock's current price.
View analysts price targets for GTBP or view top-rated stocks among Wall Street analysts.
How have GTBP shares performed in 2024?: GT Biopharma's stock was trading at $7.65 at the beginning of the year. Since then, GTBP stock has increased by 2.0% and is now trading at $7.80.
View the best growth stocks for 2024 here.
When is GT Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our GTBP earnings forecast.

How were GT Biopharma's earnings last quarter?: GT Biopharma, Inc. (NASDAQ:GTBP) announced its quarterly earnings results on Thursday, April, 15th. The company reported ($101.70) EPS for the quarter, missing analysts' consensus estimates of ($1.20) by $100.50.
When did GT Biopharma's stock split?: GT Biopharma's stock reverse split before market open on Monday, February 5th 2024. The 1-30 reverse split was announced on Monday, February 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
How do I buy shares of GT Biopharma?: Shares of GTBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GTBP) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

GT Biopharma (GTBP) Stock Price, News & Analysis

GT Biopharma MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Insider Buying vs. Insider Selling

Percentage Held by Insiders

Percentage Held by Institutions

Earnings and Valuation

Price to Book Value per Share Ratio

About GT Biopharma Stock (NASDAQ:GTBP)

GTBP Stock Price History

GTBP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

GTBP Stock Analysis - Frequently Asked Questions

Overall MarketRank^™